BREAKTHROUGH LASER FOR HAIR LOSS TREATMENT

FoLix is the first and only FDA-cleared fractional laser for hair loss treatment, offering clinics a validated, non-surgical hair loss solution to help patients improve the appearance of their scalp hair.

FoLix uses fractional laser technology to deliver precise micro-channels of thermal energy to the scalp, stimulating hair follicles and triggering a natural biological response that improves the appearance of scalp hair without damaging surrounding tissue.

FoLix is FDA-cleared for improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV who are seeking hair loss treatment.

Adult patients in early to moderate stages of hair thinning who want to improve the appearance of their scalp hair and regain their hair potential are ideal candidates for this hair loss solution.

Yes. FoLix is designed as a hair loss solution for women and men, allowing your practice to serve the entire addressable hair loss market with a single device.

Each full scalp treatment takes just 30 minutes, enabling high patient throughput and making it easy to schedule multiple sessions throughout your practice day.

Patients experience minimal discomfort – typically only a mild warming or tingling sensation – with no anesthesia required, making it a comfortable and convenient procedure.

There is no downtime. Patients may experience slight redness that typically resolves within 24 hours and can immediately return to work and daily activities.

The standard protocol consists of 4-6 sessions spaced approximately one month apart, plus 2-3 maintenance sessions to optimize and maintain clinical outcomes.

While results vary by individual, many patients report improved scalp health early on, with visible improvements in the appearance of scalp hair typically observed after the 3rd or 4th session and continued improvement following completion of the protocol.

Clinical studies show proven results including a 10-18% increase in number of hairs per cm², 13-16% of additional follicular units per cm², and no adverse events reported.

In many jurisdictions, this easily delegable non-invasive laser procedure can be performed by trained nurses or licensed aestheticians, allowing you to maximize physician time for consultations and other procedures-always verify your local regulations.

No. LLLT uses photobiomodulation, while FoLix uses fractional photothermolysis to create controlled microthermal zones and activate the scalp’s natural regenerative response. FoLix is a fundamentally different, provider-delivered approach to hair loss—not a higher-powered LLLT device.

FoLix uses controlled laser energy to activate the scalp’s natural regenerative response, offering practices a differentiated, in-office approach to hair loss management.

FoLix enables you to enter the high-demand hair loss treatment market with a recurring revenue model, short treatment times, and high patient throughput – creating strong potential for ROI.

Hair loss treatment is one of the fastest-growing segments in aesthetics. Offering the first and only FDA-cleared fractional laser for hair loss allows you to capture new patient demographics and cross-sell them into your broader aesthetic service portfolio.

Lumenis has no clinical information concerning the safety or efficacy of the combination of the FoLix laser treatment with topicals for the purpose of treatment for improvement of appearance of scalp hair due to hair loss and therefore cannot recommend it.

No. The FoLix handpiece is engineered to part and navigate through existing hair, delivering energy directly to the scalp without requiring patients to shave or trim.

The use of FoLix is contraindicated for patients with any concurrent cancer or history of skin cancer or pre-cancerous lesions at the treatment area, active infection, fungal or bacterial diseases. See the FoLix machine user manual for a complete list of contraindications and risks.